Share Price and Basic Stock Data
Last Updated: December 24, 2025, 7:16 pm
| PEG Ratio | -4.60 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Emmessar Biotech & Nutrition Ltd, operating in the chemicals sector, has exhibited a rather tumultuous revenue trajectory over recent years. For the fiscal year ending March 2025, the company reported sales of ₹0.61 Cr, a slight increase from ₹0.56 Cr in the previous year. However, when we look at the quarterly figures, the trend appears erratic. For instance, in June 2023, sales plummeted to ₹0.07 Cr, only to rebound to ₹0.34 Cr by September 2024. This volatility raises questions about the stability of Emmessar’s revenue streams. The company’s ability to consistently generate sales is further compounded by a significant operating profit margin (OPM) that has been persistently negative, hitting a staggering -300% in recent reports. This indicates that while sales are being made, the cost of doing business is eroding profits at an alarming rate, which could deter potential investors looking for stable growth.
Profitability and Efficiency Metrics
Profitability metrics for Emmessar Biotech are quite concerning. The company has reported a net profit of just ₹0.40 Cr, translating to a P/E ratio of 60.9, which seems stretched given the context of its ongoing financial struggles. The return on equity (ROE) stands at a mere 4.23%, highlighting inefficiencies in generating returns for shareholders. Notably, the company’s cash conversion cycle (CCC) has ballooned to 242.49 days, indicating a significant delay in converting investments into cash flows. This prolonged cycle may hinder operational efficiency and create liquidity challenges. Furthermore, the interest coverage ratio is extraordinarily high at 1760.67x, but this is somewhat misleading given that the company has no borrowings. A lack of debt can be a double-edged sword; while it reduces financial risk, it also suggests the company may not be leveraging opportunities for growth through strategic investments.
Balance Sheet Strength and Financial Ratios
On the balance sheet front, Emmessar presents a mixed picture. The company boasts zero borrowings, which is a significant strength, offering a cushion against interest rate fluctuations and market volatility. However, reserves are modest, standing at ₹3.00 Cr, which could limit its ability to invest in growth initiatives. The current ratio is an impressive 15.67, indicating strong liquidity and the ability to cover short-term obligations comfortably. Yet, this raises questions about whether the company is effectively utilizing its available capital. The price-to-book value ratio at 1.97x suggests that the stock may be slightly overvalued relative to its net assets. Investors might want to consider whether the high valuation is justified given the underlying financial performance, particularly the persistent operating losses and low profitability metrics.
Shareholding Pattern and Investor Confidence
Emmessar’s shareholding pattern reveals a stable control by promoters, who hold 59.53% of the company, suggesting a strong commitment to the firm’s long-term vision. However, the lack of Foreign Institutional Investors (FIIs) and minimal Domestic Institutional Investors (DIIs) presence—only 0.19%—may raise flags about wider market confidence in the stock. The public’s stake stands at 40.28%, with 7,350 shareholders, indicating a reasonably diverse ownership base. While promoter confidence is a positive sign, the low institutional interest could reflect skepticism about the company’s growth trajectory and profitability prospects. As institutional players often conduct rigorous due diligence, their absence could be interpreted as a warning signal for retail investors contemplating their positions in Emmessar.
Outlook, Risks, and Final Insight
The outlook for Emmessar Biotech & Nutrition Ltd appears to be fraught with challenges. The erratic revenue trends, coupled with consistently negative operating margins, suggest that the company is grappling with fundamental operational issues. Investors must be cautious, as the high P/E ratio amidst low profitability raises concerns about overvaluation. Additionally, the prolonged cash conversion cycle could strain liquidity, particularly if sales do not stabilize. However, the company’s zero-debt status is a silver lining, providing some room for maneuvering in challenging times. Investors might consider focusing on how Emmessar plans to address its operational inefficiencies and whether it can leverage its liquidity for growth. Ultimately, while there are some strengths, including promoter control and a solid balance sheet, the risks tied to profitability and market confidence should not be underestimated. A prudent approach would involve closely monitoring upcoming quarterly results for signs of improvement before making any investment commitments.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Fischer Medical Ventures Ltd | 2,783 Cr. | 43.2 | 125/40.8 | 139 | 5.55 | 0.01 % | 1.08 % | 0.70 % | 1.00 |
| Emmessar Biotech & Nutrition Ltd | 14.5 Cr. | 29.0 | 47.2/25.8 | 63.0 | 16.0 | 0.00 % | 12.6 % | 4.23 % | 10.0 |
| Cochin Minerals & Rutile Ltd | 207 Cr. | 264 | 356/238 | 12.3 | 211 | 3.03 % | 23.3 % | 15.0 % | 10.0 |
| Archean Chemical Industries Ltd | 6,466 Cr. | 524 | 728/408 | 31.6 | 157 | 0.57 % | 16.0 % | 12.0 % | 2.00 |
| Alufluoride Ltd | 334 Cr. | 428 | 517/376 | 16.3 | 144 | 0.70 % | 23.6 % | 20.8 % | 10.0 |
| Industry Average | 5,007.25 Cr | 544.23 | 153.55 | 160.00 | 0.49% | 13.95% | 10.65% | 7.00 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.21 | 0.07 | 0.43 | 0.32 | 0.07 | 0.08 | 0.33 | 0.08 | 0.08 | 0.34 | 0.10 | 0.10 | 0.09 |
| Expenses | 0.36 | 0.27 | 0.60 | 0.48 | 0.35 | 0.30 | 0.54 | 0.47 | 0.36 | 0.42 | 0.38 | 0.43 | 0.36 |
| Operating Profit | -0.15 | -0.20 | -0.17 | -0.16 | -0.28 | -0.22 | -0.21 | -0.39 | -0.28 | -0.08 | -0.28 | -0.33 | -0.27 |
| OPM % | -71.43% | -285.71% | -39.53% | -50.00% | -400.00% | -275.00% | -63.64% | -487.50% | -350.00% | -23.53% | -280.00% | -330.00% | -300.00% |
| Other Income | 0.44 | 0.43 | 0.44 | 0.42 | 0.46 | 0.53 | 0.53 | 0.48 | 0.46 | 0.51 | 0.43 | 0.61 | 0.53 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Profit before tax | 0.27 | 0.21 | 0.25 | 0.24 | 0.16 | 0.29 | 0.30 | 0.07 | 0.16 | 0.41 | 0.13 | 0.26 | 0.24 |
| Tax % | 25.93% | 33.33% | 108.00% | 20.83% | 68.75% | 31.03% | 56.67% | -285.71% | 43.75% | 31.71% | 84.62% | 126.92% | 25.00% |
| Net Profit | 0.20 | 0.13 | -0.02 | 0.20 | 0.05 | 0.20 | 0.13 | 0.27 | 0.09 | 0.28 | 0.02 | -0.07 | 0.17 |
| EPS in Rs | 0.40 | 0.26 | -0.04 | 0.40 | 0.10 | 0.40 | 0.26 | 0.54 | 0.18 | 0.56 | 0.04 | -0.14 | 0.34 |
Last Updated: August 19, 2025, 3:48 pm
Below is a detailed analysis of the quarterly data for Emmessar Biotech & Nutrition Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.09 Cr.. The value appears to be declining and may need further review. It has decreased from 0.10 Cr. (Mar 2025) to 0.09 Cr., marking a decrease of 0.01 Cr..
- For Expenses, as of Jun 2025, the value is 0.36 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.43 Cr. (Mar 2025) to 0.36 Cr., marking a decrease of 0.07 Cr..
- For Operating Profit, as of Jun 2025, the value is -0.27 Cr.. The value appears strong and on an upward trend. It has increased from -0.33 Cr. (Mar 2025) to -0.27 Cr., marking an increase of 0.06 Cr..
- For OPM %, as of Jun 2025, the value is -300.00%. The value appears strong and on an upward trend. It has increased from -330.00% (Mar 2025) to -300.00%, marking an increase of 30.00%.
- For Other Income, as of Jun 2025, the value is 0.53 Cr.. The value appears to be declining and may need further review. It has decreased from 0.61 Cr. (Mar 2025) to 0.53 Cr., marking a decrease of 0.08 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.02 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.02 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.24 Cr.. The value appears to be declining and may need further review. It has decreased from 0.26 Cr. (Mar 2025) to 0.24 Cr., marking a decrease of 0.02 Cr..
- For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 126.92% (Mar 2025) to 25.00%, marking a decrease of 101.92%.
- For Net Profit, as of Jun 2025, the value is 0.17 Cr.. The value appears strong and on an upward trend. It has increased from -0.07 Cr. (Mar 2025) to 0.17 Cr., marking an increase of 0.24 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.34. The value appears strong and on an upward trend. It has increased from -0.14 (Mar 2025) to 0.34, marking an increase of 0.48.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:47 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.37 | 2.19 | 1.98 | 2.61 | 1.27 | 0.63 | 3.40 | 6.99 | 0.36 | 1.02 | 0.56 | 0.61 | 0.38 |
| Expenses | 1.43 | 2.34 | 2.66 | 2.38 | 1.67 | 1.27 | 3.81 | 6.15 | 1.26 | 1.71 | 1.64 | 1.56 | 1.63 |
| Operating Profit | -0.06 | -0.15 | -0.68 | 0.23 | -0.40 | -0.64 | -0.41 | 0.84 | -0.90 | -0.69 | -1.08 | -0.95 | -1.25 |
| OPM % | -4.38% | -6.85% | -34.34% | 8.81% | -31.50% | -101.59% | -12.06% | 12.02% | -250.00% | -67.65% | -192.86% | -155.74% | -328.95% |
| Other Income | 0.09 | 0.06 | 0.03 | 0.98 | 1.25 | 1.01 | 1.21 | 1.47 | 1.92 | 1.75 | 1.99 | 2.01 | 2.11 |
| Interest | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.20 | 0.07 | 0.03 | 0.01 | 0.05 | 0.08 | 0.06 | 0.06 | 0.09 | 0.09 | 0.10 | 0.10 | 0.09 |
| Profit before tax | -0.17 | -0.16 | -0.68 | 1.19 | 0.80 | 0.29 | 0.74 | 2.25 | 0.93 | 0.97 | 0.81 | 0.96 | 0.77 |
| Tax % | 82.35% | -25.00% | -30.88% | 0.00% | -15.00% | -82.76% | -2.70% | 36.00% | 48.39% | 47.42% | 7.41% | 66.67% | |
| Net Profit | -0.31 | -0.12 | -0.47 | 1.19 | 0.91 | 0.53 | 0.75 | 1.45 | 0.48 | 0.50 | 0.75 | 0.32 | 0.23 |
| EPS in Rs | -0.62 | -0.24 | -0.94 | 2.38 | 1.82 | 1.06 | 1.50 | 2.90 | 0.96 | 1.00 | 1.50 | 0.64 | 0.46 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 61.29% | -291.67% | 353.19% | -23.53% | -41.76% | 41.51% | 93.33% | -66.90% | 4.17% | 50.00% | -57.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | -352.96% | 644.86% | -376.72% | -18.23% | 83.27% | 51.82% | -160.23% | 71.06% | 45.83% | -107.33% |
Emmessar Biotech & Nutrition Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -12% |
| 5 Years: | -29% |
| 3 Years: | 19% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | -20% |
| 3 Years: | -13% |
| TTM: | -42% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 15% |
| 3 Years: | 2% |
| 1 Year: | -35% |
| Return on Equity | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 11% |
| 3 Years: | 7% |
| Last Year: | 4% |
Last Updated: September 5, 2025, 3:21 pm
Balance Sheet
Last Updated: December 4, 2025, 2:49 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Reserves | -3.42 | -3.62 | -4.09 | -2.91 | -2.01 | -1.49 | -0.73 | 0.70 | 1.17 | 1.67 | 2.41 | 2.71 | 3.00 |
| Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.08 | 0.11 | 0.00 | 0.00 |
| Other Liabilities | 0.65 | 1.03 | 1.36 | 1.13 | 0.92 | 1.59 | 1.86 | 2.11 | 1.04 | 1.19 | 1.23 | 1.51 | 1.52 |
| Total Liabilities | 2.23 | 2.41 | 2.27 | 3.22 | 3.91 | 5.17 | 6.13 | 7.81 | 7.21 | 7.94 | 8.75 | 9.22 | 9.52 |
| Fixed Assets | 1.58 | 1.42 | 0.73 | 0.72 | 2.25 | 1.99 | 1.91 | 1.86 | 2.07 | 2.00 | 1.91 | 1.81 | 1.77 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.80 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Other Assets | 0.64 | 0.98 | 1.53 | 1.69 | 1.65 | 3.17 | 4.21 | 5.94 | 5.13 | 5.93 | 6.83 | 7.40 | 7.74 |
| Total Assets | 2.23 | 2.41 | 2.27 | 3.22 | 3.91 | 5.17 | 6.13 | 7.81 | 7.21 | 7.94 | 8.75 | 9.22 | 9.52 |
Below is a detailed analysis of the balance sheet data for Emmessar Biotech & Nutrition Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.00 Cr..
- For Reserves, as of Sep 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.71 Cr. (Mar 2025) to 3.00 Cr., marking an increase of 0.29 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1.52 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.51 Cr. (Mar 2025) to 1.52 Cr., marking an increase of 0.01 Cr..
- For Total Liabilities, as of Sep 2025, the value is 9.52 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9.22 Cr. (Mar 2025) to 9.52 Cr., marking an increase of 0.30 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1.77 Cr.. The value appears to be declining and may need further review. It has decreased from 1.81 Cr. (Mar 2025) to 1.77 Cr., marking a decrease of 0.04 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01 Cr..
- For Other Assets, as of Sep 2025, the value is 7.74 Cr.. The value appears strong and on an upward trend. It has increased from 7.40 Cr. (Mar 2025) to 7.74 Cr., marking an increase of 0.34 Cr..
- For Total Assets, as of Sep 2025, the value is 9.52 Cr.. The value appears strong and on an upward trend. It has increased from 9.22 Cr. (Mar 2025) to 9.52 Cr., marking an increase of 0.30 Cr..
Notably, the Reserves (3.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.06 | -0.15 | -0.68 | 0.23 | -0.40 | -0.71 | -0.41 | 0.84 | -0.90 | -0.77 | -1.19 | -0.95 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 45.29 | 6.67 | 66.36 | 5.59 | 8.62 | 23.17 | 3.22 | 141.51 | 10.14 | 3.58 | 13.04 | 11.97 |
| Inventory Days | 267.67 | 335.80 | 136.88 | 121.67 | 52.14 | 2,049.62 | 272.56 | 7.24 | 196.54 | 127.75 | 164.25 | 230.53 |
| Days Payable | 121.67 | 150.87 | 76.04 | 76.04 | 5.79 | 1,628.46 | 189.61 | 51.70 | 56.15 | 0.00 | 18.25 | 0.00 |
| Cash Conversion Cycle | 191.29 | 191.60 | 127.20 | 51.22 | 54.97 | 444.33 | 86.18 | 97.05 | 150.52 | 131.33 | 159.04 | 242.49 |
| Working Capital Days | 29.31 | 38.33 | 22.12 | 85.31 | 175.31 | 457.70 | 30.06 | 79.37 | -60.83 | 114.51 | 91.25 | 35.90 |
| ROCE % | -9.60% | -10.81% | -39.30% | 80.00% | 31.50% | 17.66% | 25.48% | 45.14% | 15.67% | 15.02% | 11.35% | 12.61% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.61 | 1.48 | 0.99 | 0.94 | 2.88 |
| Diluted EPS (Rs.) | 0.61 | 1.48 | 0.99 | 0.94 | 2.88 |
| Cash EPS (Rs.) | 0.82 | 1.70 | 1.20 | 1.14 | 3.02 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 15.43 | 14.82 | 13.34 | 12.35 | 11.41 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 15.43 | 14.82 | 13.34 | 12.35 | 11.41 |
| Revenue From Operations / Share (Rs.) | 1.22 | 1.11 | 2.04 | 0.73 | 13.99 |
| PBDIT / Share (Rs.) | 2.11 | 1.82 | 2.12 | 2.05 | 4.63 |
| PBIT / Share (Rs.) | 1.92 | 1.63 | 1.94 | 1.86 | 4.51 |
| PBT / Share (Rs.) | 1.92 | 1.63 | 1.94 | 1.86 | 4.51 |
| Net Profit / Share (Rs.) | 0.63 | 1.50 | 1.01 | 0.95 | 2.90 |
| PBDIT Margin (%) | 172.92 | 163.94 | 104.05 | 280.54 | 33.07 |
| PBIT Margin (%) | 156.94 | 146.36 | 94.86 | 255.24 | 32.25 |
| PBT Margin (%) | 156.85 | 146.36 | 94.86 | 255.24 | 32.25 |
| Net Profit Margin (%) | 51.75 | 135.01 | 49.43 | 130.25 | 20.73 |
| Return on Networth / Equity (%) | 4.10 | 10.12 | 7.55 | 7.70 | 25.43 |
| Return on Capital Employeed (%) | 10.96 | 9.86 | 12.85 | 13.53 | 35.20 |
| Return On Assets (%) | 3.42 | 8.57 | 6.34 | 6.58 | 18.57 |
| Total Debt / Equity (X) | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 |
| Asset Turnover Ratio (%) | 0.06 | 0.06 | 0.13 | 0.04 | 1.00 |
| Current Ratio (X) | 15.67 | 13.56 | 14.14 | 14.73 | 3.85 |
| Quick Ratio (X) | 15.41 | 13.38 | 13.82 | 14.52 | 3.80 |
| Inventory Turnover Ratio (X) | 5.74 | 0.56 | 0.67 | 0.24 | 4.14 |
| Interest Coverage Ratio (X) | 1760.67 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (Post Tax) (X) | 528.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Enterprise Value (Cr.) | 8.31 | 8.78 | 7.28 | 9.16 | 4.87 |
| EV / Net Operating Revenue (X) | 13.61 | 15.81 | 7.14 | 25.09 | 0.69 |
| EV / EBITDA (X) | 7.87 | 9.64 | 6.87 | 8.94 | 2.11 |
| MarketCap / Net Operating Revenue (X) | 24.85 | 26.74 | 12.16 | 37.65 | 1.05 |
| Price / BV (X) | 1.97 | 2.01 | 1.86 | 2.23 | 1.29 |
| Price / Net Operating Revenue (X) | 24.87 | 26.75 | 12.16 | 37.67 | 1.05 |
| EarningsYield | 0.02 | 0.05 | 0.04 | 0.03 | 0.19 |
After reviewing the key financial ratios for Emmessar Biotech & Nutrition Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 5. It has decreased from 1.48 (Mar 24) to 0.61, marking a decrease of 0.87.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 5. It has decreased from 1.48 (Mar 24) to 0.61, marking a decrease of 0.87.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 3. It has decreased from 1.70 (Mar 24) to 0.82, marking a decrease of 0.88.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 15.43. It has increased from 14.82 (Mar 24) to 15.43, marking an increase of 0.61.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 15.43. It has increased from 14.82 (Mar 24) to 15.43, marking an increase of 0.61.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1.22. It has increased from 1.11 (Mar 24) to 1.22, marking an increase of 0.11.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 2.11. This value is within the healthy range. It has increased from 1.82 (Mar 24) to 2.11, marking an increase of 0.29.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.92. This value is within the healthy range. It has increased from 1.63 (Mar 24) to 1.92, marking an increase of 0.29.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.92. This value is within the healthy range. It has increased from 1.63 (Mar 24) to 1.92, marking an increase of 0.29.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.63. This value is below the healthy minimum of 2. It has decreased from 1.50 (Mar 24) to 0.63, marking a decrease of 0.87.
- For PBDIT Margin (%), as of Mar 25, the value is 172.92. This value is within the healthy range. It has increased from 163.94 (Mar 24) to 172.92, marking an increase of 8.98.
- For PBIT Margin (%), as of Mar 25, the value is 156.94. This value exceeds the healthy maximum of 20. It has increased from 146.36 (Mar 24) to 156.94, marking an increase of 10.58.
- For PBT Margin (%), as of Mar 25, the value is 156.85. This value is within the healthy range. It has increased from 146.36 (Mar 24) to 156.85, marking an increase of 10.49.
- For Net Profit Margin (%), as of Mar 25, the value is 51.75. This value exceeds the healthy maximum of 10. It has decreased from 135.01 (Mar 24) to 51.75, marking a decrease of 83.26.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.10. This value is below the healthy minimum of 15. It has decreased from 10.12 (Mar 24) to 4.10, marking a decrease of 6.02.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.96. This value is within the healthy range. It has increased from 9.86 (Mar 24) to 10.96, marking an increase of 1.10.
- For Return On Assets (%), as of Mar 25, the value is 3.42. This value is below the healthy minimum of 5. It has decreased from 8.57 (Mar 24) to 3.42, marking a decrease of 5.15.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.01 (Mar 24) to 0.00, marking a decrease of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.06. There is no change compared to the previous period (Mar 24) which recorded 0.06.
- For Current Ratio (X), as of Mar 25, the value is 15.67. This value exceeds the healthy maximum of 3. It has increased from 13.56 (Mar 24) to 15.67, marking an increase of 2.11.
- For Quick Ratio (X), as of Mar 25, the value is 15.41. This value exceeds the healthy maximum of 2. It has increased from 13.38 (Mar 24) to 15.41, marking an increase of 2.03.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.74. This value is within the healthy range. It has increased from 0.56 (Mar 24) to 5.74, marking an increase of 5.18.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1,760.67. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 1,760.67, marking an increase of 1,760.67.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 528.00. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 528.00, marking an increase of 528.00.
- For Enterprise Value (Cr.), as of Mar 25, the value is 8.31. It has decreased from 8.78 (Mar 24) to 8.31, marking a decrease of 0.47.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 13.61. This value exceeds the healthy maximum of 3. It has decreased from 15.81 (Mar 24) to 13.61, marking a decrease of 2.20.
- For EV / EBITDA (X), as of Mar 25, the value is 7.87. This value is within the healthy range. It has decreased from 9.64 (Mar 24) to 7.87, marking a decrease of 1.77.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 24.85. This value exceeds the healthy maximum of 3. It has decreased from 26.74 (Mar 24) to 24.85, marking a decrease of 1.89.
- For Price / BV (X), as of Mar 25, the value is 1.97. This value is within the healthy range. It has decreased from 2.01 (Mar 24) to 1.97, marking a decrease of 0.04.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 24.87. This value exceeds the healthy maximum of 3. It has decreased from 26.75 (Mar 24) to 24.87, marking a decrease of 1.88.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to 0.02, marking a decrease of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Emmessar Biotech & Nutrition Ltd:
- Net Profit Margin: 51.75%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.96% (Industry Average ROCE: 13.95%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.1% (Industry Average ROE: 10.65%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 528
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 15.41
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 63 (Industry average Stock P/E: 153.55)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 51.75%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Inorganic - Others | Plot No.T-3/2, Raigad District Maharashtra 410208 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Srinivasa Raghavan Mathurakavi Ayyangar | Managing Director |
| Mr. Jeyavel B Nadar | Executive Director |
| Dr.(Mrs.) Sarada S Raghavan | Non Executive Director |
| Dr.(Mrs.) Anuradha S Raghavan | Non Executive Director |
| Mr. Milind Sitaram Desai | Ind. Non-Executive Director |
| Mr. Veeraraghavan Ranganathan | Ind. Non-Executive Director |
| Mr. Dinesh Kumar Deora | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Emmessar Biotech & Nutrition Ltd?
Emmessar Biotech & Nutrition Ltd's intrinsic value (as of 24 December 2025) is 34.79 which is 19.97% higher the current market price of 29.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 14.5 Cr. market cap, FY2025-2026 high/low of 47.2/25.8, reserves of ₹3.00 Cr, and liabilities of 9.52 Cr.
What is the Market Cap of Emmessar Biotech & Nutrition Ltd?
The Market Cap of Emmessar Biotech & Nutrition Ltd is 14.5 Cr..
What is the current Stock Price of Emmessar Biotech & Nutrition Ltd as on 24 December 2025?
The current stock price of Emmessar Biotech & Nutrition Ltd as on 24 December 2025 is 29.0.
What is the High / Low of Emmessar Biotech & Nutrition Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Emmessar Biotech & Nutrition Ltd stocks is 47.2/25.8.
What is the Stock P/E of Emmessar Biotech & Nutrition Ltd?
The Stock P/E of Emmessar Biotech & Nutrition Ltd is 63.0.
What is the Book Value of Emmessar Biotech & Nutrition Ltd?
The Book Value of Emmessar Biotech & Nutrition Ltd is 16.0.
What is the Dividend Yield of Emmessar Biotech & Nutrition Ltd?
The Dividend Yield of Emmessar Biotech & Nutrition Ltd is 0.00 %.
What is the ROCE of Emmessar Biotech & Nutrition Ltd?
The ROCE of Emmessar Biotech & Nutrition Ltd is 12.6 %.
What is the ROE of Emmessar Biotech & Nutrition Ltd?
The ROE of Emmessar Biotech & Nutrition Ltd is 4.23 %.
What is the Face Value of Emmessar Biotech & Nutrition Ltd?
The Face Value of Emmessar Biotech & Nutrition Ltd is 10.0.